Stocks and Investing Stocks and Investing
Fri, June 22, 2012
Thu, June 21, 2012

Market Maker Surveillance Report. ONXX, ARNA, CRME, PFCB, AERS, EEDG, Highest Net Buy Volume With Lowest Price Friction For Th


Published on 2012-06-21 18:01:31 - WOPRAI
  Print publication without navigation


June 21, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3388 companies with "abnormal" market making, 1362 companies with positive Friction Factors and 4595 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. ONYX PHARMACEUTICALS, INC. (NASDAQ:ONXX), ARENA PHARMACEUTICALS INC (NASDAQ:ARNA), CARDIOME PHARMA CORP (NASDAQ:CRME), PF CHANG'S CHINA BISTRO INC (NASDAQ:PFCB), AERIUS INC (OTC:AERS), ENERGY EDGE TECH CORPORATION (OTC:EEDG). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  ONXX    $19.270   43.23%    11,011,695   48.60%    9,737,367    42.98%    1,274,328    661     
  ARNA    $1.200    11.43%    30,205,364   50.92%    28,926,135   48.77%    1,279,229    10,660  
  CRME    $0.060    15.38%    1,702,726    81.12%    396,352      18.88%    1,306,374    217,729 
  PFCB    $0.010    0.02%     1,797,463    68.03%    844,707      31.97%    952,756      952,756 
  AERS    $0.021    696.67%   9,961,193    54.43%    8,340,911    45.57%    1,620,282    775,255 
  EEDG    $0.030    63.33%    1,665,909    67.44%    804,170      32.56%    861,739      283,467 
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows ONXX with a Net Buy Volume of 1,274,328 shares and a Friction Factor of 661 shares. That means that it takes 661 more shares of buying than selling to move ONXX higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Thursday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish.

ONYX PHARMACEUTICALS, INC. (NASDAQ:ONXX) - Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. Its developing products include Nexavar for the treatment of liver cancer, kidney cancer, non-small cell lung cancer, thyroid cancer, breast cancer, ovarian cancer, and colorectal cancer; and Carfilzomib for the treatment of multiple myeloma and solid tumor. The company also develops ONX 0801, a Phase 1 clinical stage product, under a development and license agreement with BTG International Limited; and ONX 0912, an oral proteasome inhibitor. In addition, it develops ONX 0914, a preclinical stage product for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. In addition, Onyx Pharmaceuticals, through a development collaboration, option, and license agreement with S*BIO Pte Ltd, owns options to license the rights of ONX 0803 and ONX 0805. ONX 0803 is an orally available, potent, and selective inhibitor of JAK2; and ONX 0805 is a JAK2 inhibitor. Further, the company has a research and development collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore the control of, or otherwise intervene in, the misregulated cell cycle in tumor cells. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Emeryville, California.

ARENA PHARMACEUTICALS INC (NASDAQ:ARNA) - Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin that has completed Phase III clinical trials for the treatment of weight management; APD791, an anti-thrombotic drug candidate, which completed Phase Ia and Phase Ib clinical trials; APD597 that is in Phase I clinical trials for the treatment of type II diabetes; APD916, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. The companys drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including Constitutively Activated Receptor Technology and Melanophore Technology. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop compounds for the potential treatment of type II diabetes and other disorders; and Merck & Co., Inc. to develop therapeutics for atherosclerosis and other disorders. Arena Pharmaceuticals also has a strategic cooperation agreement with Siegfried Ltd to manufacture lorcaserin. The company was founded in 1997 and is based in San Diego, California.

CARDIOME PHARMA CORP (NASDAQ:CRME) - Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. to develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

PF CHANG'S CHINA BISTRO INC (NASDAQ:PFCB) - P.F. Chang's China Bistro, Inc., through its subsidiaries, engages in the ownership and operation of restaurants in the United States. The company owns and operates two restaurant concepts, P.F. Chang's China Bistro and Pei Wei Asian Diner. As of January 2, 2011, it owned and operated 201 full service Bistro restaurants and 168 quick casual Pei Wei restaurants; and operated 7 Bistro restaurants in Mexico and the Middle East under development and licensing agreements. The company was founded in 1996 and is based in Scottsdale, Arizona.

AERIUS INC (OTC:AERS) - Aerius International, Inc. operates as a cell phone engineering, product design, and marketing company in the United States and internationally. It provides communication technologies for cellular handset and other mobile wireless communication devices for civilian and military applications. The company offers antennas for cell phones. Aerius International is based in Las Vegas, Nevada.

ENERGY EDGE TECH CORPORATION (OTC:EEDG) -

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net

Contributing Sources